<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114250">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827267</url>
  </required_header>
  <id_info>
    <org_study_id>PUMA-NER-4201</org_study_id>
    <secondary_id>2012-004743-68</secondary_id>
    <nct_id>NCT01827267</nct_id>
  </id_info>
  <brief_title>Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Puma Biotechnology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Puma Biotechnology, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter,
      multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus
      combination therapy in patients with non-small cell lung cancer (NSCLC) who have documented
      somatic HER2 mutations and who have received at least one prior cytotoxic chemotherapy
      regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, therapeutic-exploratory, adaptive design, open-label, multicenter,
      multinational study evaluating neratinib monotherapy and neratinib plus temsirolimus
      combination therapy in patients with NSCLC who have documented somatic HER2 mutations and
      who have received at least one prior cytotoxic chemotherapy regimen. Patients will be
      randomized at study entry into 1 of 2 treatment arms:

        -  Arm A: neratinib 240 mg orally once daily,

        -  Arm B: neratinib 240 mg orally once daily plus temsirolimus 8 mg once weekly by
           intravenous (IV) infusion.

      In the case of disease progression, patients initially assigned to the neratinib monotherapy
      arm will be given the option to add temsirolimus 8 mg IV once weekly.

      All patients on combination therapy may be dose-escalated with respect to temsirolimus dose
      to 15 mg/week at the end of first cycle of treatment with the combination, if well tolerated
      and at the physician's discretion. In the event that the neratinib 240 mg/day plus
      temsirolimus 15 mg/week dose is not well tolerated, the patient will be subsequently dose
      reduced back to neratinib 240 mg/day plus temsirolimus 8 mg/week.

      Dosing will be continuous on nominal 3-week cycles until evidence of progressive disease,
      unacceptable toxicity, or patient withdrawal of consent.

      All eligible patients enrolled will have their disease measured radiographically at
      baseline. Patients will undergo radiographic evaluation of their disease every 6 weeks until
      disease progression or withdrawal from the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>minimum 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR is defined as Complete Response (CR) and Partial Response (PR) after receiving at least one prior regimen of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>at least 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>CBR is defined as the percentage of patients with CR plus PR plus Stable Disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Estimated 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR is defined as the date when criterion of CR or PR is first met and subsequently confirmed (whichever status is recorded first) to the first date of documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Estimated 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Estimated 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events [AEs] and Serious Adverse Events [SAEs])</measure>
    <time_frame>Estimated 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life measured using EQ-5D-5L and FACT-L</measure>
    <time_frame>Estimated 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Validated Quality of Life Questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>HER2-mutant Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg neratinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>240 mg neratinib plus 8 mg temsirolimus with optional dose escalation to 15 mg temsirolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neratinib</intervention_name>
    <description>240 mg orally, once daily with food, continuously in 21 day cycles</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>8 mg or 15 mg weekly by IV infusion</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 years at the time of signing the informed consent.

          -  Histologically confirmed diagnosis of NSCLC, advanced (stage IIIB) or metastatic
             (stage IV).

          -  Documented somatic ErbB2 (HER2) activating mutation.

        Exclusion Criteria:

          -  Previous treatment with any investigational agent ≤30 days prior to the initiation of
             investigational products.

          -  Prior exposure to tyrosine kinase inhibitor including neratinib, lapatinib, and
             afatinib (excluding dacomitinib), or mTOR inhibitor.

        Note: There are additional inclusion and exclusion criteria.  The study center will
        determine if you meet all of the criteria.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Puma Biotechnology Clinical Operations</last_name>
    <phone>+1-424-248-6500</phone>
    <email>clinicaltrials@pumabiotechnology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusettes General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble Hopital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hopital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux universitaires de Strasbourg Nouvel Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>167091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Toulous Hopital Larre</name>
      <address>
        <city>Toulouse</city>
        <zip>30030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Puma</keyword>
  <keyword>neratinib</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
